Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.39 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GLB1 | P16278 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230075 | 1.00 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL18498636 | 0.86 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL23386481 | 0.82 | CHRM2 (0.39) | MAN1B1CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL28807483 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL30323250 | 0.80 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL14655735 | 0.80 | MAN1B1 (0.43) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL28671488 | 0.78 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL28670729 | 0.78 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL14690441 | 0.78 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA | |
| SCHEMBL14690437 | 0.78 | MAN1B1 (0.42) | MAN1B1FUCA1GBA1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1375496-B1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | EISAI R&D MAN CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| US-7112593-B2 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI CO., LTD. (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1375496-A1 | N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072830-A1 | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | COASY, HCCS, SQLE | MAN1B1 1492/4885FUCA1 852/4885GBA1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.